Main Article Content

Authors

Objective: To describe the sociodemographic characteristics and symptoms in Colombian patients with chronic myeloproliferative neoplasms. Methods: The authors used the information contained in the validation exercise symptom scale mpn-saf tss —myeloproliferative neoplasm symptom assessment form the total symptom score—, which, through a survey methodology in 62 patients diagnosed with these malignancies level in Colombia, provided the input analysis to achieve the objective of this study. Results: Among the socio-demographic characteristics, the age variable accounted for 59% of the patients included in the study over 60 years, with a mean of 58.8 (sd 15.53). Increased frequency and severity of symptoms in patients diagnosed with polycythemia vera were identified, followed by essential thrombocythemia and finally in patients diagnosed with myelofibrosis. “Fatigue” was expressed in 98% of patients to be the main symptom registered on the scale used in this study. Conclusion: The patients in the study had a mean age of 59 years with a higher proportion of women by 58% and a low level of schooling of 40%. The total number of symptoms referred to in the scale occurred in more than 70% of the patients, being the most frequent fatigue, early satiety and concentration problems.
Salguero Peña E., Enciso Olivera, L. J., & Lozano Apache, T. (2018). Characterization and Symptoms of Patients in Colombia with Chronic Myeloproliferative Neoplasm. Revista Ciencias De La Salud, 16(1), 59–68. https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.6490

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer [Internet]. 2006 feb. [Citado 2014 nov. 4]; 106(3):631-5. Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/16369984

Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an olmsted county study 1976 – 1995. AJH. 1999;61:10-15.

Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood [Internet]. 2013 jun. [citado 2014 nov. 4]; 121(24):4832-7. Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/23570800

Mesa R, Verstovsek S, Cervantes F. Primary myelofibrosis (pmf), post polycythemia vera myelofibrosis (post-pv mf), post essential thrombocythemia myelofibrosis (post-et mf), blast phase pmf (pmf). Leukemia Research. 2007;31(6):737-40 [Internet]. [citado 2014 nov. 4]. Disponible en: http://www.sciencedirect.com/science/article/pii/S0145212606004693

Lozano T, Salguero E, Wiesner C. Validación de la escala abreviada de carga de síntomas en pacientes con neoplasias mieloproliferativas (mpn saf tss): evaluación en pacientes colombianos. Inf. inédito. Bogota: ciic Consultores S.A.S; 2013.

Development Core Team. A language and environment for statistical computing. Vienna: Foundation for Statistical Computing; 2008. Disponible en: http://www.R-project.org

Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative Neoplasm (mpn) symptom assessment form total symptom score: prospective interna- tional assessment of an abbreviated symptom burden scoring system among patients with mpns. J Clin Oncol. 2012;30(33):4098-103.

Downloads

Download data is not yet available.